Review



ddavp  (Ferring Pharmaceuticals)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Ferring Pharmaceuticals ddavp
    Ddavp, supplied by Ferring Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/desmopressin/ddavp/pmc12830292-22-14-11
    Average 86 stars, based on 1 article reviews
    ddavp - by Bioz Stars, 2026-09
    86/100 stars

    Images

    Related Articles

    other:

    Article Title: Alert: misinformation that may hurt patients with both adrenal insufficiency and AVP deficiency.
    Article Snippet: Additionally, it reads: “DDAVP Injection is contraindicated in patients with hyponatremia (or a history of hyponatremia), with excessive fluid intake (e.g., polydipsia), using loop diuretics or systemic or inhaled glucocorticoids”.. No reference is provided to support such statement regarding glucocorticoids, and similar alert is not present in oral or nasal spray desmopressin package inserts by the same manufacturer.. In fact, we know that the opposite is true, and that in AVPD polyuria may be masked by adrenal insufficiency and uncovered when GCs are administered.

    Article Title: 18th Annual Congress of the European Association for Haemophilia and Allied Disorders 2025, 4-7 February 2025, Milan, Italy.
    Article Snippet: Speaker Abstracts Main Congress SPK27 Workshop on Ultrasound: Joint Health in Haemophilia Where AreWe Going J. Blatny1, R. Gualtierotti2, Angelo Bianchi3, M. Timmer4, C. Martinoli5, M. Friberg Birkedal6, R. Carioli7 1Paediatric Haematology and Biochemisty, Children’s University Hospital and Masaryk University, Brno, Czech Republic; 2Department of Pathophysiology and Transplantation, Universita degli Studi di Milano, Milan, Italy; 3Bonomi Haemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; 4van Creveldkliniek, University Medical Center, Utrecht, Netherlands; 5University of Genova, Genova, Italy; 6Rigshospitalet, University Hospital Haemophilia Center, Copenhagen, Denmark; 7Department of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy Summary of Your Presentation: The workshop titled “Ultrasound: Joint Health in Haemophilia Where Are We Going?” offers a comprehensive exploration of the evolving role of ultrasound for joint health in haemophilia patients, with specific focus on using ultrasound as a point-of-care device.. By highlighting advancements in ultrasound technology and their critical impact on patient outcomes, the session focuses on key innovations and clinical applications.. Co-chaired by Jan Blatny and Roberta Gualtierotti, the workshop begins with a recap of Allied Health Professionals Day, presented by Nanda Uitslager, Ruth Elise Dybvik Matlary, and Christina Burgess, highlighting the importance of collaborative efforts in multidisciplinary care.

    Article Title: Long-Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use-Results Survey in Japan.
    Article Snippet: Desmopressin orally disintegrating tablets (ODT, 25 and 50 μg; MINIRINMELT; Ferring Pharmaceuticals, Parsippany, NJ) were approved in Japan in June 2019 and launched in September 2019 for the treatment of nocturia due to NP in men.

    Article Title: Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan
    Article Snippet: Desmopressin orally disintegrating tablets (ODT, 25 and 50 μg; MINIRINMELT; Ferring Pharmaceuticals, Parsippany, NJ) were approved in Japan in June 2019 and launched in September 2019 for the treatment of nocturia due to NP in men.

    Injection:

    Article Title: Short-term severe polyuria responsive to vasopressin after hypoglycaemia and hypotension in a domestic shorthair cat
    Article Snippet: .. On day 5, the patient was given a low dose of desmopressin (4 μg/ml, DDAVP Injection; Ferring Pharmaceuticals) ( ) for both therapeutic and diagnostic purposes. ..

    Diagnostic Assay:

    Article Title: Short-term severe polyuria responsive to vasopressin after hypoglycaemia and hypotension in a domestic shorthair cat
    Article Snippet: .. On day 5, the patient was given a low dose of desmopressin (4 μg/ml, DDAVP Injection; Ferring Pharmaceuticals) ( ) for both therapeutic and diagnostic purposes. ..



    Similar Products

    ddavp  (Ferring Pharmaceuticals)
    86
    Ferring Pharmaceuticals ddavp
    Ddavp, supplied by Ferring Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/desmopressin/ddavp/pmc12830292-22-14-11
    Average 86 stars, based on 1 article reviews
    ddavp - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    desmopressin acetate hydrate  (Ferring Pharmaceuticals)
    86
    Ferring Pharmaceuticals desmopressin acetate hydrate
    Desmopressin Acetate Hydrate, supplied by Ferring Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/desmopressin/desmopressin/pmc12830292-22-0-11
    Average 86 stars, based on 1 article reviews
    desmopressin acetate hydrate - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    desmopressin acetate ddavp  (Ferring Pharmaceuticals)
    86
    Ferring Pharmaceuticals desmopressin acetate ddavp
    Desmopressin Acetate Ddavp, supplied by Ferring Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/desmopressin/desmopressin/pmc12830292-705-3-8
    Average 86 stars, based on 1 article reviews
    desmopressin acetate ddavp - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    desmopressin odt  (Ferring Pharmaceuticals)
    86
    Ferring Pharmaceuticals desmopressin odt
    Flowchart of patients included in the survey. The safety analysis set comprised 1049 patients who had received <t>desmopressin</t> and for whom case report forms were collected by the end of March 2022.
    Desmopressin Odt, supplied by Ferring Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/desmopressin/desmopressin/pmc12995508-160-15-0
    Average 86 stars, based on 1 article reviews
    desmopressin odt - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    desmopressin  (Ferring Pharmaceuticals)
    86
    Ferring Pharmaceuticals desmopressin
    Flowchart of patients included in the survey. The safety analysis set comprised 1049 patients who had received <t>desmopressin</t> and for whom case report forms were collected by the end of March 2022.
    Desmopressin, supplied by Ferring Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/desmopressin/desmopressin/pmc12995508-157-0-10
    Average 86 stars, based on 1 article reviews
    desmopressin - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    nephrology desmopressin  (Wolters Kluwer Health)
    86
    Wolters Kluwer Health nephrology desmopressin
    Flowchart of patients included in the survey. The safety analysis set comprised 1049 patients who had received <t>desmopressin</t> and for whom case report forms were collected by the end of March 2022.
    Nephrology Desmopressin, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/desmopressin/desmopressin+nephrology/10__34067_slash_kid__0000001185-112-13-2
    Average 86 stars, based on 1 article reviews
    nephrology desmopressin - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Flowchart of patients included in the survey. The safety analysis set comprised 1049 patients who had received desmopressin and for whom case report forms were collected by the end of March 2022.

    Journal: Lower Urinary Tract Symptoms

    Article Title: Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan

    doi: 10.1111/luts.70052

    Figure Lengend Snippet: Flowchart of patients included in the survey. The safety analysis set comprised 1049 patients who had received desmopressin and for whom case report forms were collected by the end of March 2022.

    Article Snippet: Ferring Japan has previously reported interim PMS results on the safety of long‐term use of desmopressin ODT in 300 patients included in the safety analysis set, followed for up to 12 weeks post‐treatment [ ].

    Techniques:

    Desmopressin continuation status and reasons for discontinuation during the first 12 weeks of treatment (A, B) and during weeks 12–52 weeks (C, D).

    Journal: Lower Urinary Tract Symptoms

    Article Title: Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan

    doi: 10.1111/luts.70052

    Figure Lengend Snippet: Desmopressin continuation status and reasons for discontinuation during the first 12 weeks of treatment (A, B) and during weeks 12–52 weeks (C, D).

    Article Snippet: Ferring Japan has previously reported interim PMS results on the safety of long‐term use of desmopressin ODT in 300 patients included in the safety analysis set, followed for up to 12 weeks post‐treatment [ ].

    Techniques:

    Response to hyponatremia and subsequent patient outcomes. (A) Response following the onset of hyponatremia after administration of desmopressin for up to 12 weeks. (B) Time to recover of hyponatremia in patients who developed hyponatremia from desmopressin administration to 12 weeks. (C) Outcomes of hyponatremia event. (D) Frequency of patient outcomes by interventions for desmopressin. (E) Time from discontinuation or termination of desmopressin administration to recovery or resolution of symptoms.

    Journal: Lower Urinary Tract Symptoms

    Article Title: Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan

    doi: 10.1111/luts.70052

    Figure Lengend Snippet: Response to hyponatremia and subsequent patient outcomes. (A) Response following the onset of hyponatremia after administration of desmopressin for up to 12 weeks. (B) Time to recover of hyponatremia in patients who developed hyponatremia from desmopressin administration to 12 weeks. (C) Outcomes of hyponatremia event. (D) Frequency of patient outcomes by interventions for desmopressin. (E) Time from discontinuation or termination of desmopressin administration to recovery or resolution of symptoms.

    Article Snippet: Ferring Japan has previously reported interim PMS results on the safety of long‐term use of desmopressin ODT in 300 patients included in the safety analysis set, followed for up to 12 weeks post‐treatment [ ].

    Techniques:

    Flowchart of patients included in the survey. The safety analysis set comprised 1049 patients who had received desmopressin and for whom case report forms were collected by the end of March 2022.

    Journal: Lower Urinary Tract Symptoms

    Article Title: Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan

    doi: 10.1111/luts.70052

    Figure Lengend Snippet: Flowchart of patients included in the survey. The safety analysis set comprised 1049 patients who had received desmopressin and for whom case report forms were collected by the end of March 2022.

    Article Snippet: Desmopressin orally disintegrating tablets (ODT, 25 and 50 μg; MINIRINMELT; Ferring Pharmaceuticals, Parsippany, NJ) were approved in Japan in June 2019 and launched in September 2019 for the treatment of nocturia due to NP in men.

    Techniques:

    Desmopressin continuation status and reasons for discontinuation during the first 12 weeks of treatment (A, B) and during weeks 12–52 weeks (C, D).

    Journal: Lower Urinary Tract Symptoms

    Article Title: Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan

    doi: 10.1111/luts.70052

    Figure Lengend Snippet: Desmopressin continuation status and reasons for discontinuation during the first 12 weeks of treatment (A, B) and during weeks 12–52 weeks (C, D).

    Article Snippet: Desmopressin orally disintegrating tablets (ODT, 25 and 50 μg; MINIRINMELT; Ferring Pharmaceuticals, Parsippany, NJ) were approved in Japan in June 2019 and launched in September 2019 for the treatment of nocturia due to NP in men.

    Techniques:

    Response to hyponatremia and subsequent patient outcomes. (A) Response following the onset of hyponatremia after administration of desmopressin for up to 12 weeks. (B) Time to recover of hyponatremia in patients who developed hyponatremia from desmopressin administration to 12 weeks. (C) Outcomes of hyponatremia event. (D) Frequency of patient outcomes by interventions for desmopressin. (E) Time from discontinuation or termination of desmopressin administration to recovery or resolution of symptoms.

    Journal: Lower Urinary Tract Symptoms

    Article Title: Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan

    doi: 10.1111/luts.70052

    Figure Lengend Snippet: Response to hyponatremia and subsequent patient outcomes. (A) Response following the onset of hyponatremia after administration of desmopressin for up to 12 weeks. (B) Time to recover of hyponatremia in patients who developed hyponatremia from desmopressin administration to 12 weeks. (C) Outcomes of hyponatremia event. (D) Frequency of patient outcomes by interventions for desmopressin. (E) Time from discontinuation or termination of desmopressin administration to recovery or resolution of symptoms.

    Article Snippet: Desmopressin orally disintegrating tablets (ODT, 25 and 50 μg; MINIRINMELT; Ferring Pharmaceuticals, Parsippany, NJ) were approved in Japan in June 2019 and launched in September 2019 for the treatment of nocturia due to NP in men.

    Techniques: